“Lenacapavir is a product with real transformational potential that has the power to change the history of HIV,” Carolyn Amole of the Clinton Health Access Initiative (CHAI) told last week’s 13th ...

Cuts in US funding for HIV programmes have already led to declines in testing and treatment starts in several countries, research presented last week at the 13th International AIDS Society ...

More than half of people who received a pair of broadly neutralising antibodies (bnAbs) plus the immune-modulating drug N-803 (Anktiva) had delayed viral rebound or maintained a low or suppressed ...

Two studies of children with HIV presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda showed that even if they are on antiretroviral therapy (ART) ...

Artifical intelligence (AI) featured prominently at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda last week. Experts expressed excitement – and some ...

Key points When drugs interact it can impact the effectiveness and side effects of either drug. The anti-HIV drugs ritonavir and cobicistat have the most interactions. Discussing recreational drugs ...

A study presented at the recent 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018) aims to quantify how many people with HIV there might be in the community who both have a ...

Once again, a life expectancy study has shown that HIV-positive people who start antiretroviral therapy (ART) promptly and have good access to medical care live as long as their HIV-negative peers.

Over half of funding for anti-gender actors in Europe appears to come from within Europe itself, with significant amounts of money also flowing from the US and the Russian Federation, according to ...

A man in southern California, dubbed the 'City of Hope patient', appears to be the latest person cured of HIV after receiving a stem cell transplant from a donor with a rare mutation, bringing the ...

South Africa’s public sector will save US$326 million over the next three years as a result of competitive tendering exercise that pushed the price of a fixed combination of tenofovir, lamivudine and ...

The results from the Ipergay study of intermittent pre-exposure prophylaxis (PrEP) were published in the New England Journal of Medicine (NEJM) on 1 December, World AIDS Day. The journal-published ...